How NATROX® was born
The inventor of our technology, Mel, had an aging aunt suffering in pain for months due to a venous leg ulcer that refused to heal. After confiding how much indescribable pain she endured, Mel wanted to find some way to help her. He knew if her wound would heal, she could be relieved of so much daily misery. And so began his quest to learn how wounds healed.
After much research, he realized oxygen was the secret to healing. He was determined to use this secret to help heal his aunt.
But how could he get oxygen near a wound without applying any pressure or chemicals to the skin? This would be key to avoid any negative side effects. Of course, he didn’t want to make things worse!
After consulting friends at the University of Cambridge, our inventor and his small team masterminded the technology today known as NATROX® O₂. This topical oxygen therapy leverages the natural properties of oxygen to stimulate healing.
In an effort to share this solution, they formed a company with a mission to develop innovative medical technology designed to help patients. Because, surely, there were people just like Mel struggling to find a solution for a hard-to-heal wounds.
Today, our mission is to transform the quality of life for anyone with a chronic wound.
Because everyone deserves the chance to heal.
Chronic wounds affect millions worldwide. Our mission is to transform the lives of patients suffering from hard-to-heal wounds through our innovative technology.
Passion for medicine, compassion for patients, respect among employees, and commitment to customers drives our success and enables us to restore hope to those who need it most.
Meet the team
Our team has a unique passion for health care and deep compassion for patients.
Get to know our team. We can help you take the next step forward in wound care.
Craig has deep insight into the wound care market combined with a proven track record of building businesses. He served as CEO of MolecuLight, a Canadian wound care start-up that developed and launched an imaging device capable of detecting bacteria in wounds.
He also served as VP, Business Development and Strategy for UK-based Systagenix, an established provider of advanced wound care (AWC) products. When the firm was purchased by Acelity, a global AWC company, Craig was a key player facilitating the acquisition.
More recently, Craig was named a 10 Best Inspiring CEO of 2020 for his global approach, commercial credibility, customer focus, and clear communication across all stakeholder groups.
John brings over 20 years of experience in medical device manufacturing having worked in multiple European and Asian countries where he delivered process and transactional improvements across manufacturing, supply chain, quality, and procurement. He is responsible for manufacturing operations, quality, and product development.
Specialising in Lean manufacturing, Six-Sigma, Kaizen, and process improvement, colleagues across his career continue to praise John for his strong leadership skills. He understands how to nurture individual strengths and talents, ultimately encouraging team members to think strategically, innovate, and take action.
Group Financial Controller
As Group Financial Controller, Phil plays a vital role in ensuring the financial stability and success of our organization. His strategic insights and business acumen contribute to our continuous growth and drive successful transformations in the wound care industry.
Phil brings a wealth of expertise in finance, system and process change, strategic planning, project management, and stakeholder engagement. With over 18 years’ experience, Phil is a highly qualified chartered accountant (FCA) since 2004, dedicated to delivering successful transformations for organizations.
Before joining NATROX®, Phil made significant contributions as a Director at Rosaris Ltd, a consultancy specialising in finance and tax management for small to medium-sized businesses, playing a pivotal role in fostering growth for numerous enterprises. Prior to that, Phil served as the Senior Finance Manager at EasyJet, a prominent British airline group with extensive global reach. Phil’s commitment to making a difference in the healthcare sector is evident from his time at the Wellcome Trust, a charitable foundation focused on health research. During his impressive 12-year tenure, Phil’s remarkable abilities within the Finance team were recognized with multiple promotions.
Bringing a positive attitude and a great sense of humour, Phil is renowned among colleagues for his willingness to go above and beyond to achieve shared goals. His expertise in relationship building and strategic planning makes him an invaluable asset to the NATROX® team.
VP Sales, North America
Chris is responsible for implementing sales strategy, developing product reimbursement strategy across the USA, and penetrating new market segments to drive organisational growth and profitability. He has a long track record of consistently exceeding revenue targets while maintaining a clear focus on strategy.
Prior to NATROX®, he was the VP of Sales at Imbed Biosciences, a medical device company developing innovative solutions for wound care. He also worked in senior sales and marketing roles at Pure & Clean which develops solutions for the wound care market, Innovacyn which is known for developing innovative technologies for wound healing, and TEI Biosciences which manufacture implantable devices to support soft tissue regeneration.
VP, Global Marketing
Nancy is a strategic, customer-focused marketing leader with a proven track record for driving top-line growth and long-term market sustainability.
Prior to NATROX®, Nancy worked at Medela, the world’s leading medical vacuum technology manufacturer based in Switzerland. During her tenure there, Nancy held the position of Director of Marketing for the Healthcare Division and was responsible for marketing strategy, sales enablement, and clinical solutions for Negative Pressure Wound Therapy (NPWT), Cardiothoracic surgery, and PVS Airway products. Her work experience also includes marketing executive and leadership positions at GE Healthcare Ultrasound, GE Capital, GE Medical Protective, and hospital networks including Advocate Health and Loyola Health Systems.
Nancy will bring her experience from larger organisations to help scale the business globally. She has a solid understanding of the challenges facing the wound care industry and a deep understanding of our customers.
Dr. Emma Woodmansey
Global Clinical Specialist
Emma is responsible for formulating and implementing the company’s clinical strategy. She also contributes to new product design, risk assessments, and instructions-for-use development, all aimed at improving patient outcomes.
Emma joins the NATROX® team after having served in various clinical and healthcare leadership roles over the past 20 years. Most recently she was Medical Affairs Manager, leading the omnichannel education content for Antivirals, at Pfizer UK. Previously she worked for Smith & Nephew in multiple roles including Clinical Strategy Director and Lead Microbiologist for R&D in their Advanced Wound Care Division using scientific and clinical evidence to frame critical issues and shape consensus.
With her background in the fields of microbiology, infection, and advanced wound care, Emma makes valuable contributions to the company’s chief objective – helping patients with wounds regain their lives as quickly as possible.
Global Business Unit Director
After successfully commercializing NATROX® O2 in the UK market, Nick’s current focus is driving the strategic direction of the NATROX® Wound Care brand by supporting its global market opportunities and the development of new technologies.
Before joining the company, Nick was Global Category Director for Acelity, managing several market-leading global wound care brands, growing them to a revenue of +$120M.
His career in healthcare spans 24 years and includes roles in the NHS, SCA Hygiene Products (Essity) and healthcare communications, plus international sales & marketing positions for Mölnlycke Healthcare and ConvaTec, leading medical solutions companies.
Director, Human Resources
Sandy brings +20 years of HR experience, with more than half her career in leading Life Sciences firms such as Amgen, Abcam, and Novartis. She has a strong interest in health care on both a professional and personal level, serving as a volunteer at The Hospice Biographers, and supporting students move from education into employment in Life Sciences with Form the Future.
Sandy has developed successful HR strategies for organizations of varying sizes with locations across the globe. Her role is pivotal for Inotec’s expansion. She is responsible for developing HR strategies and system, managing employee relations and recruiting and onboarding staff.
Director, US Strategic Accounts
Prior to joining Inotec, Bruce was a medical, cardiac device and kidney dialysis services professional with St. Jude Medical/Abbott Vascular, Johnson and Johnson and DaVita, maintaining national sales and corporate accounts responsibilities. Prior to moving into the medical device arena in 2005, Bruce was in the telecommunications industry at Corning, Inc. with responsibilities that ranged from Sales Engineering to VP of Sales and Marketing. Bruce drives organizational relevance partnership & growth via planning, analysis, strategic relationships and decisive execution.
General Manager, Asia
Lamine manages Inotec Asia, our Southeast Asian sales headquarters based in Kuala Lumpur, Malaysia. His team’s focus is to provide innovative therapies for people suffering chronic wounds across the region.
Originally serving as a NATROX® distributor, after Lamine witnessed the positive healing impact our products had on wounds first-hand, he later decided to join the Inotec family. Lamine brings an intense passion for sales, a strong customer-focus, and a creative approach.
Sales Director, EMEA & LATAM
David brings over 14 years of experience in medical devices across a range of areas including dental, respiratory, and diagnostic. Although his main experience is in sales, he has also held positions in product marketing, giving him a well-rounded understanding of customer needs.
With a proven track record of setting up distributor networks in the medical device field across EMEA, David plays a pivotal role maximising business opportunities and bringing a stronger overall focus to the EMEA and LATAM regions.
Dr. Thomas Serena, MD FACS FACHM MAPWCA
Chief Medical Officer
Founder and Medical Director of The SerenaGroup®, a group of wound care clinics, Dr. Serena is a vascular surgeon and long-time proponent of hyperbaric oxygen therapy. The internationally recognised expert in the field of wound healing has been the lead or Principal Investigator in over 100 clinical trials. He has a vast knowledge of oxygen therapy and understands its positive impact on chronic wounds.
Dr. Serena has published more than 200 papers and given more than 1,000 lectures worldwide. His well-decorated tenure includes past-President of the Association for the Advancement of Wound Care (AAWC) and the American Professional Wound Care Association, former board member of the Wound Healing Society, and also Vice-President of the American College of Hyperbaric Medicine. He has also developed a diagnostic technique to collect proteases from chronic wounds, called The Serena Technique©.
Dr. Gregory Schultz
Chief Scientific Officer
Dr. Schultz is Professor Emeritus at the University of Florida where he served as Director of the Institute for Wound Research and Professor of Obstetrics and Gynecology. His extensive research primarily focuses on the regulators of normal wound healing and understanding the role bacterial biofilms and proteases play in impairing wound healing. Dr Schultz has authored or co-authored over 400 publications that have been cited over 23,000 times. He has received $38 million in grant support as a principal- or co-investigator, is an inventor on 36 patents, and was elected a Fellow of the National Academy of Inventors. He served as President of the Wound Healing Society and served on the National Pressure Injury Advisory Panel.
Dr. Windy Cole, DPM
Director, Global Medical Affairs
Dr. Cole has been a practising physician in wound care for over 22 years. She is an adjunct professor and Director of Wound Care Research at Kent State University College of Podiatric Medicine. Board certified by the American Board of Foot and Ankle Surgery and the American Board of Wound Management, Dr. Cole has published numerous peer-reviewed and industry articles and is a sought-after speaker worldwide. She is also a feature writer for Podiatry Management, Today’s Wound Clinic, and a contributing writer for Podiatry Today.
She has been a dedicated wound care advocate for two decades with interests focused on medical education, diabetic foot care, wound care, limb salvage, & clinical research. Her passion to help others has led her to participate in humanitarian efforts including a medical mission to Jordan in 2018 to aid the large Syrian refugee population seeking asylum from civil war. On the forefront of wound research, she was the 2020 World Union of Wound Healing Silver Medal Award recipient for her work in Technology-Driven Research and the 2022 recipient of the Kaplan-Kanat Memorial Lecture Award.
She holds a bachelor’s degree in biology from the University of Cincinnati where she graduated summa cum laude. She is also an honour graduate of Kent State University College of Podiatric Medicine.
Professor Keith Harding
World renown as “Godfather of Wound Care,” the highly acclaimed professor has a longstanding interest in wound healing. His clinical practice focusses exclusively on treating patients with wound healing problems with a wide range of aetiologies. He has held numerous external professorial appointments at universities across the UK, Australia, and Singapore. Editor-in-Chief of the International Wound Journal, Prof. Harding has written extensively about wound healing, having authored over 600 publications and written several chapters and books.
Appointed the first Director of the Wound Healing Research Unit in 1991, Prof. Harding went on to serve as Dean of Clinical Innovation at Cardiff University from 2013 to 2018. He was quickly appointed to Medical Director of the Welsh Wound Innovation Centre in 2014, and later appointed as Senior Advisor for Clinical Innovation for Cardiff & Vale University Health Board in 2021.
Prof. Harding has received numerous awards throughout his career, most notably, a total of £200M of grant funding for developing clinical innovation in wound healing. Awarded the CBE in the New Year Honours list in 2013 for Services to Medicine and Health Care, later that year he received £4.2M to establish the Welsh Wound Innovation Initiative, which enabled the creation of the first clinically-focused wound healing centre in the world. In 2014, he was awarded The Learned Society of Wales Fellowship. In 2018, Prof. Harding and his team received a £24M European grant to establish a clinical innovation ecosystem across South Wales. In 2018, he was appointed Senior Clinical Research Director at the A Star Institute in Singapore and a SG$28M wound programme grant.
Despite retiring from academic and clinical practice in the United Kingdom 2022, Prof. Harding continues his passion to advance clinical innovation in wound care. In 2023, he was appointed an independent member of the Cardiff & Vale University Health Board, advises several wound healing and clinical innovation projects, and teaches across Asia, Australia, Europe, and North America.
Dr. Adrian Parton, MBE
Adrian Parton is a Director of Objective Imaging Ltd (Hardware Software Automation business), AB-Polyblok Ltd (novel dementia drug), Toxibact Ltd (novel antimicrobial) and Chairman/Owner of Ivy House Country House Hotel. He has a PhD in Molecular Virology and has been in industry for the last 25 years. He has successfully grown technology based businesses from concept through to production and into multi-national businesses.
Michael Clancy has 35 years’ experience in marketing, sales and general management within European medical devices with specialist knowledge and experience within the medical beds, pressure redistribution and wound care sectors. He is currently non-executive director at Medstrom Ltd and Inotec AMD Limited.
Pierre Socha is an early-stage technology investor with Amadeus Capital Partners. He invests in digital health, medical technologies, autonomous systems, augmented reality, cyber security and artificial intelligence. He currently sits on the boards of Doctify, Repositive, Lumeon, PhoreMost and Congenica.
Supporting the Patient Journey – Podiatry Management Nov 2023
November 07, 2023
Podcast: Pain and the Journey of the Chronic Wound Patient
November 07, 2023
Consensus on the Clinical Efficacy and Guidelines of Continuous Topical Oxygen Therapy for Wounds – JoWC LATAM Oct 2023
November 02, 2023
Holistic Approach to a Wound Care Patient
November 01, 2023
The Efficacy of Continuous Topical Oxygen Therapy in the Treatment of Challenging Diabetic Foot Ulcers; A Case Series
November 01, 2023
Management of Chronic Radiation Tissue Necrosis Wounds with Continuous Topical Oxygen Therapy Supports Wound Healing in Patients of Advanced Age
October 10, 2023
Supporting the Patient Journey: The Use of Topical Oxygen Therapy in Chronic Wound Pain Management
October 10, 2023
New Expert Consensus: Topical Oxygen Therapy in Wound Healing
August 18, 2023
Case Series Examining the Efficacy of cTOT in Treatment of DFUs
May 23, 2023
NATROX® O₂ Now Available in South Korea
August 17, 2023
New Expert Guidelines from IWGDF Highlight the Growing International Recognition of Topical Oxygen Therapy (TOT) for Diabetic Foot Ulcers
May 16, 2023
Raise Healthcare Named UK Distributor for NATROX® Wound Care
April 27, 2023
Chris Lyon Joins NATROX® Wound Care as VP Sales, North America
April 17, 2023
Dr. Windy Cole, DPM Joins NATROX® Wound Care as Director of Global Medical Affairs
March 28, 2023
Health Technology Wales Guidance Advises Routine Adoption of NATROX® O₂
December 13, 2022
Nancy Stahulak Joins NATROX® Wound Care as VP of Global Marketing
March 15, 2023
New Expert Opinion in Support of Topical Oxygen Therapy (TOT)
November 21, 2022
Delphi Consensus on Guidelines for the Use of Topical Oxygen
November 07, 2022
How wound care clinicians can optimize clinical outcomes and resources
October 10, 2022
NATROX® O₂ Masterclass Guide
August 23, 2022
NATROX® Wound Care Ranks Number One for its Innovative Medical Technology
August 15, 2022
New NATROX® IQ Video Now Available
August 10, 2022
PRHOINSA Appointed Exclusive Distributor in Spain for NATROX® Wound Care
July 13, 2022
New Evidence in Support of Topical Oxygen Therapy (TOT)
July 06, 2022
NATROX® Wound Care Expands into the Digital Arena with the Launch of NATROX® IQ
June 20, 2022
John Adam Joins NATROX® Wound Care as Chief Operating Officer
June 08, 2022
New study shows substantial pain relief with NATROX® O₂
May 11, 2022
Dr. Thomas Serena Joins NATROX® Wound Care Team as Chief Medical Officer
May 04, 2022
NATROX® Wound Care Appoints Eminent Wound Care and Biofilm Expert, Dr. Gregory Schultz, as Chief Scientific Officer
April 05, 2022
Inotec AMD Moves to Larger Office to Prepare for US Growth
July 18, 2021
Get in Touch
Complete this form to hear from our team. By using this form, you agree with our data storage and handling policy.